- Pharmaceutical Executive: June 2024
- Volume 44
- Issue 6
Opposite Spectrums
Our June issue of Pharmaceutical Executive offers a uniquely diverse range of coverage and voices—a "sum-of-its-parts" balance that's not always easy to pull off.
In our
Our June issue is a perfect example, and we hope you find the coverage a little extra special. We first offer an
As you can imagine, in classic Cuban style, he’s honest and direct. And, as far as his company’s mission—providing a transparent, affordable Rx buying option (with 2,200 drugs available and growing)—he’s focused on the moment.
Two additional June coverage pieces feature themes and people on the other end of the healthcare and motivation spectrums—the manufacturer and developer sides. But those, too, are each diverse from the other. One is our
So a little old with a little new. The commercial jockeying of Big Pharma and the innovation impact of emerging biotech. Power and promise.
We hope all our coverage this month delivers some valuable and useful food for thought. As always, thanks for reading.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Articles in this issue
over 1 year ago
Beyond the Numbers: Extrapolating Today’s Trends Forwardover 1 year ago
Pharmaceutical Executive: June 2024 Issue (PDF)over 1 year ago
2024 Pharm Exec Top 50 Companiesover 1 year ago
Craig Tooman: Silencing the Distractionsover 1 year ago
Regaining Trust in the Pharma Industryover 1 year ago
The Healthcare System is Changing—So How Should We Respond?over 1 year ago
Biotech Performance Remains Tethered to Rate Expectationsover 1 year ago
Pharm Exec Exclusive: Mark Cuban Talks Drug PricingNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.